A recent large, population-based comparative analysis examined outcomes for patients treated with percutaneous ablation, partial nephrectomy, or radical nephrectomy.
Renal Cell Carcinoma
A new frailty assessment tool can aid in the prognosis of urologic cancer patients, its inventors say.
“The high initial complete response rate and durability observed in the interim analysis is very promising and suggests that UGN-101 could be an effective and well-tolerated noninvasive treatment for patients with UTUC,” says researcher Seth Paul Lerner, MD.
An analysis of trends in the management of renal masses shows growing use of active surveillance, although some data suggest “a proportion of surveillance cases may have been due to lack of access to care instead of truly choosing active surveillance,” says study author Ketan K. Badani, MD.
The approval of immune checkpoint inhibitor combination therapy may be the most significant advance in a decade for the treatment of metastatic renal cell carcinoma, an expert says.
While they may have potential anti-tumor effects in other cancers, non-steroidal anti-inflammatory drugs do not appear to confer a survival benefit in metastatic renal cell carcinoma.
High levels of visceral fat were associated with a significantly increased risk of death in women with clear cell renal cell carcinoma, but not in men, results of a recent retrospective study show.
“The findings should serve as a call to action for urologic specialists who care for patients with cancer,” says Alexander Kutikov, MD.
A recent study suggests experimental "texture analysis" of renal masses via computed tomography scan holds promise as a technique to allow more effective risk stratification.
"In the end, it is up to the surgeons who wish to continue to perform these robotic procedure to demonstrate their cost-effectiveness," writes Badar M. Mian, MD.